Full Year 2025 Novozymes A/S Earnings Call Transcript
Key Points
- Novonesis (Novozymes) B (NVZMF) achieved a strong 7% organic sales growth in 2025, despite a 1% negative impact from exiting certain countries.
- The company delivered an adjusted EBITDA margin of 37.1%, aligning with their initial outlook despite significant currency headwinds.
- Emerging markets showed robust growth at 9%, driven by increased local presence and tailored solutions.
- The integration of the Feed Enzyme Alliance acquisition is progressing well, contributing positively to the company's performance.
- Novonesis launched 33 new Biosolutions in 2025, with significant innovations in Food & Beverages and Household Care, aligning with consumer demand for healthier and sustainable solutions.
- The company faced significant currency headwinds, impacting the adjusted EBITDA margin by approximately 0.5 percentage points.
- Exiting certain countries negatively impacted organic sales growth by around 1 percentage point for the year.
- The adjusted gross margin improvement was partially offset by increased operating expenses due to reinvestment in commercial presence.
- The fourth quarter saw a decline in the EBITDA margin due to one-off expenses related to realignment activities in plant operations.
- The outlook for 2026 includes potential softness in consumer behavior, particularly in the US, which could impact growth.
Ladies and gentlemen, welcome to the Novonesis' full-year financial statement for 2025 and annual report for 2025.
I'm Moore, the Chorus call operator.
(Operator Instructions)
The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Tobias Cornelius Bjorklund, Head of Investor Relations. Please go ahead, sir.
/-
So thank you, operator, and good morning, everyone, and welcome to the Novonesis' conference call for 2025.
As mentioned, my name is Tobias Bjorklund, I'm heading up Investor Relations here at Novonesis.
In this call, our CEO, Ester Baiget, and our CFO, Rainer Lehmann, will review our performance for the year as well as the outlook for 2026.
Attending today's call, we also have Tina Fanø, EVP of Planetary Health Biosolutions; Henrik Jørck Nielsen, EVP of Human Health Biosolutions; Andrew Taylor, EVP of Food and Beverage Biosolutions; and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
